Core Viewpoint - The company announced a share reduction plan by its controlling shareholder and an associated investment fund, which will not affect the company's control structure [1] Group 1: Share Reduction Details - The controlling shareholder, You Hongtao, and Shanghai Tiancheng Investment Management Co., Ltd. will reduce their holdings by a total of 7,395,445 shares, representing 1.77% of the company's total share capital [1] - You Hongtao will reduce his holdings by 5,965,965 shares, accounting for 1.43% of the total share capital [1] - The Tiancheng Tianli No. 1 Private Securities Investment Fund will reduce its holdings by 1,429,480 shares, which is 0.34% of the total share capital [1] Group 2: Compliance and Control - The share reduction plan was executed within the pre-disclosed limit and did not lead to any change in the company's control [1]

证券代码：002907 证券简称：华森制药 公告编号：2026-004 重庆华森制药股份有限公司 关于公司产品完成境内生产药品备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日从国家药品监督管 理局（以下简称"国家药监局"）网站查询获知公司产品克唑替尼胶囊完成境内 生产药品备案（延长药品有效期申请），并于国家药监局网站公示备案信息。现 将相关情况公告如下： 一、药品基本信息 （一）延长药品有效期申请 1.克唑替尼胶囊 药 品 通 用 名 称：克唑替尼胶囊 备 案 号：渝备 2025059388 药 品 批 准 文 号 / 原 料 药 登 记 号 ：国药准字 H20255702 上 市 许 可 持 有 人：重庆华森制药股份有限公司 上市许可持有人地址：重庆市荣昌区工业园区 生 产 企 业 名 称：重庆华森制药股份有限公司 生 产 企 业 地 址：重庆市荣昌区工业园区 二、药品其他相关情况 本次产品有效期延长，将有利于公司提升产品的市场竞争力，从而更好地在 市场进行推广，满足市场需求。 四、风险提示 上述 ...

Core Viewpoint - The article discusses the regulatory actions taken by the Chongqing Securities Regulatory Bureau against two accounting firms, Dahua and Zhonghua, for deficiencies in their audit practices, highlighting the importance of compliance with auditing standards and the need for improved quality control in financial reporting [1][9]. Group 1: Dahua Accounting Firm - Dahua Accounting Firm faced issues during the audit of Chongqing Huasen Pharmaceutical Co., Ltd.'s 2023 financial statements, including incomplete documentation in risk assessment and inadequate execution of substantive procedures [4][6]. - Specific deficiencies included incomplete risk assessment forms, insufficient evidence for control tests in the procurement and payment cycle, and inadequate substantive testing for inventory impairment and valuation [5][6]. - The firm was found to have violated multiple auditing standards and regulations, leading to the issuance of a warning letter and a requirement to enhance compliance and quality control measures [7]. Group 2: Zhonghua Accounting Firm - Zhonghua Accounting Firm encountered problems while auditing Chongqing Shunbo Aluminum Alloy Co., Ltd.'s 2024 financial report, particularly in risk assessment and substantive procedures [9][10]. - The audit documentation lacked records for reassessing materiality based on significant post-balance sheet events, and there were failures in executing revenue cutoff tests and impairment testing for receivables and inventory [11][12]. - Similar to Dahua, Zhonghua was also issued a warning letter for non-compliance with auditing standards, emphasizing the need for stricter adherence to regulations and improved audit quality [12].

Group 1 - The core viewpoint of the news is that Huason Pharmaceutical (002907) has made significant announcements regarding its subsidiary's recognition as a high-tech enterprise, drug re-registration approvals, and shareholder equity changes, all of which indicate stable operations and control [1][2] Group 2 - Huason Pharmaceutical's wholly-owned subsidiary, Chongqing Huason Yino Biotechnology Co., Ltd., has been recognized as a national high-tech enterprise for the first time, with a certificate valid for three years, allowing it to pay corporate income tax at a reduced rate of 15%, which will lower operational costs and support R&D in the biopharmaceutical sector [1] - The company announced that eight of its drugs, including injectable moxifloxacin and sodium cytidine diphosphate, have passed re-registration, covering critical clinical needs in areas such as anti-infection and cardiovascular treatment, with the approval numbers valid until 2031, ensuring normal production and sales in the future [1] Group 3 - The equity change announcement revealed that the controlling shareholder, Chengdu Dajian, and its concerted parties plan to reduce their holdings by a total of 20.8799 million shares, accounting for 5% of the company's total share capital, decreasing their combined shareholding from 70% to 65%, while the controlling shareholder and actual controller remain unchanged, with no significant impact on operations [2] - The reduced holdings have generated approximately 353 million yuan in cash based on the weighted average stock price during the period, and some shareholders' remaining reduction plans will be executed at an opportune time [2]

Group 1 - The core announcement is that Huason Pharmaceutical's subsidiary, Chongqing Huason Inno Biotechnology Co., Ltd., has been recognized as a national high-tech enterprise for the year 2025, with a certificate number GR202551102448 and a validity period of three years [2] Group 2 - The recognition was issued by the National High-tech Enterprise Recognition Management Work Leading Group, indicating the company's compliance with national standards for high-tech enterprises [2] - This recognition may enhance the company's reputation and potentially lead to increased investment opportunities and funding [2] - The announcement reflects the company's ongoing commitment to innovation and development in the biotechnology sector [2]

Core Viewpoint - Huason Pharmaceutical's subsidiary, Huason Inno, has been recognized as a national high-tech enterprise for the first time, which may enhance its market position and innovation capabilities [1] Group 1 - Huason Inno is a wholly-owned subsidiary of Huason Pharmaceutical [1] - The recognition is part of the third batch of national high-tech enterprises for the year 2025, as announced by the National High-tech Enterprise Recognition Management Work Leading Group [1] - The certificate number for this recognition is GR202551102448, and it is valid for three years [1]

Core Viewpoint - The announcement from Huason Pharmaceutical (002907.SZ) reveals significant shareholding changes involving its controlling shareholder Chengdu Dijiang and associated parties, indicating a planned reduction in their stake in the company [1][2]. Shareholding Changes - Prior to the changes, the information disclosure obligors collectively held 292,317,525 shares, representing 70.00% of Huason Pharmaceutical's total share capital [2]. - From January 23, 2025, to January 13, 2026, Chengdu Dijiang plans to reduce its holdings by 14,373,176 shares (3.44% of total share capital), while You Hongtao and the Tiancheng Tianli No.1 Private Fund will reduce their holdings by 5,965,965 shares (1.43%) and 540,780 shares (0.13%) respectively [2]. Financial Impact - The weighted average price of Huason Pharmaceutical shares during the reduction period is reported at 16.894 yuan per share, leading to an estimated total reduction amount of approximately 352.75 million yuan [2]. Future Reduction Plans - The information disclosure obligors have plans for further share reductions within the next 12 months, with You Hongtao intending to sell up to 6,649,826 shares (1.59%) and the Tiancheng Tianli No.1 Fund planning to reduce its holdings by up to 5,878,000 shares (1.41%) [3][4]. - The total planned reduction from these parties is capped at 12,527,826 shares, which is 3% of Huason Pharmaceutical's total share capital [4].

Core Viewpoint - Huason Pharmaceutical's subsidiary, Huason Inno, has been recognized as a national high-tech enterprise for the first time, which may enhance its market position and innovation capabilities [1] Group 1 - Huason Inno is a wholly-owned subsidiary of Huason Pharmaceutical [1] - The recognition is part of the third batch of national high-tech enterprises for the year 2025, as announced by the National High-tech Enterprise Recognition Management Work Leading Group [1] - The certificate number for this recognition is GR202551102448, and it is valid for three years [1]

Core Viewpoint - The company, Watson Pharmaceuticals, has received approval from the Chongqing Municipal Drug Administration for the re-registration of eight pharmaceutical products, indicating a positive regulatory development for the company [1] Group 1: Approved Products - The approved products include: - Injection of Moxifloxacin Mesylate (0.2g and 0.4g) - Injection of Cytidine Diphosphate Choline - Injection of Acyclovir - Xylometazoline Capsules - Injection of Bumetanide - Injection of Calcium Leucovorin (25mg and 100mg) [1]

关于公司收到药品再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监 督管理局（以下简称"市药监局"）核准签发的关于公司 8 个药品的《药品再注 册批准通知书》。现将相关情况公告如下： 一、《药品再注册批准通知书》主要信息 （一）注射用甲磺酸培氟沙星（0.2g） 药 品 通 用 名 称：注射用甲磺酸培氟沙星 英 文 名 / 拉 丁 名：Pefloxacin Mesylate for Injection 注 册 分 类：化学药品：原 4 类 证券代码：002907 证券简称：华森制药 公告编号：2026-003 重庆华森制药股份有限公司 药 品 注 册 标 准 编 号：《中国药典》2010 年版第二部 药 品 批 准 文 号：国药准字 H20163076 药 品 有 效 期：24 个月 药 品 批 准 文 号 有 效 期：至 2031 年 01 月 18 日 审 批 结 论：经审查，同意本品再注册。由于本品长期未生产， 恢复生产前，持有人应按相关文件要求完成有关 工作，并向市药 ...